Abstract
A group of 73 patients with advanced renal cell carcinoma, treated in different phase II trials with interferon α and/or interleukin-2, have been evaluated to identify potential baseline prognostic factors predicting their survival. The eligibility criteria were very similar across studies and included ECOG performance status ≤2, measurable or evaluable disease and no CNS metastases. The overall response rate was 8%. The overall survival was 33% at 2 years and 18% at 1 year. In the univariate analysis three prognostic factors were correlated with disease outcome: ECOG performance status (0 versus ≥1), time from diagnosis to treatment (≤12 months versus >12 months) and number of metastatic sites (1 versus ≥2). Multivariate analysis identified ECOG performance status and number of metastatic sites as important prognostic factors for survival. The true impact on patient survival of the selection of patients rather than the treatment itself should be evaluated in controlled trials.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Abbreviations
- IFN :
-
interferon
- IL :
-
interleukin
- RCC :
-
renal cell carcinoma
- PS :
-
performance status
References
Atzopodien J, Poliwoda H, Kirchner H (1991) Alpha-interferon and interleukin-2 in renal cell carcinoma: studies in nonhospitalized patients. Semin Oncol 18 [Suppl 7]:108–112
Buter J, Sleijfer DT, Graaf WTA van der, Vries EGE de, Willemse PHB, Mulder NH (1993) A progress report on the outpatient treatment of patients with advanced renal cell carcinoma using subcutaneous recombinant interleukin-2. Semin Oncol 20 [Suppl 9]:16–21
Buzaid AC, Todd MB (1989) Therapeutic options in renal cell carcinoma. Semin Oncol 16:12–19
Cox DR (1972) Regression models and life tables (with discussion). J R Statist Soc [B] 34:187–202
Elson PJ, Witte RS, Trump DL (1988) Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. Cancer Res 48:7310–7313
Fossa SD, Kramar A, Droz J-P (1994) Prognostic factors and survival in patients with metastatic renal cell carcinoma treated with chemotherapy or interferon-α. Eur J Cancer 30: 1310–1314
Horoszewicz JS, Murphy GP (1989) An assessment of the current use of human interferons in therapy of urological cancers. J Urol 142:1173–1180
Jones M, Philip T, Palmer P, von der Maase H, Vinke J, Elson P, Franks CR, Selby P (1993) The impact of interleukin-2 on survival in renal cancer: a multivariate analysis. Cancer Biother 8:275–288
Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Statist Assoc 53:457–481
Linehan WM, Shipley WU, Parkinson DR (1993) De Vita VT, Hellman S, Rosenberg SA (eds) Cancer of the kidney and ureter in Cancer: principles and practice of oncology, 4th edn. Lippincott, Philadelphia
Lissoni P, Barni S, Ardizzoia A, Crispino S, Paolorossi F, Andres M, Scardino E, Tancini G (1994) Prognostic factors of the clinical response to subcutaneous immunotherapy with interleukin-2 alone in patients with metastatic renal cell carcinoma. Oncology 51:59–62
Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719–748
Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47:207–214
Oliver RTD (1994) Renal cell cancer: is there long-term survival advantage from cytokine treatment? Eur J Cancer 30A:1214–1216
Palmer PA, Vinke J, Evers P, Pourreau C, Oskam R, Roest G, Vlems F, Becker L, Loriaux E, Franks CR (1992a) Continuous infusion of recombinant interleukin-2 with or without autologous lymphokine activated killer cells for the treatment of advanced renal cell carcinoma. Eur J Cancer 28A:1038–1044
Palmer PA, Vinke J, Philip T, Negrier S, Atzopodien J, Kirchner H, Oskam R, Franks CR (1992b) Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2. Ann Oncol 3:475–480
Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high dose interleukin-2 alone. N Engl J Med 316:889–897
Rosenberg SA, Lotze MT, Hule JJ (1988) New approaches to the immunotherapy of cancer using interleukin-2. Ann Intern Med 108:853–864
Rosenberg SA, Lotze MT, Young JC, Topalian SL, Chang AE, Schwartzentruber DJ, Aebersold P, Leitman S, Linehan WM, Seipp CA (1993) Prospective randomized trial of high-dose interleukin-2 alone or in combination with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst 85:622–632
Vuoristo M, Jantunen I, Pyrhönen S, Muhonen T, Kellokumpu-Lehtinen P (1994) A combination of subcutaneous recombinant interleukin-2 and recombinant interferon-α in the treatment of advanced renal cell carcinoma or melanoma. Eur J Cancer 30A:530–532
Weiss GR, Margolin KA, Aronson FR, Sznol M, Atkins MB, Dutcher JP, Gaynor ER, Boldt DH, Doroshow JH, Bar MH, Hawkins MJ, Demchak PA, Gucalp R, Fisher RI (1992) A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma. J Clin Oncol 10:275–281
West WH, Tauer KW, Yannelli JR, Marshall GD, Orr DW, Thurman GB, Oldham RK (1987) Constant infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 316:898–905
Yagoda A (1989) Chemotherapy of renal cell carcinoma: 1983–1989. Semin Urol 7:199–206
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Canobbio, L., Rubagotti, A., Miglietta, L. et al. Prognostic factors for survival in patients with advanced renal cell carcinoma treated with interleukin-2 and interferon-α. J Cancer Res Clin Oncol 121, 753–756 (1995). https://doi.org/10.1007/BF01213322
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01213322